Over the past decade, our knowledge regarding the cellular and molecular mechanisms involved in NASH- and NAFLD-associated HCC development has grown, spotlighting GLP-1 RAs, which had originally emerged as drugs for the management of diabetes, as potential candidates for the treatment of HCC. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.